Literature DB >> 32721537

Targeting kinases with thymoquinone: a molecular approach to cancer therapeutics.

Syeda Samira Afrose1, Md Junaid2, Yeasmin Akter3, Mousumi Tania4, Meiling Zheng5, Md Asaduzzaman Khan6.   

Abstract

Kinases are enzymes that are important for cellular functions, but their overexpression has strong connections with carcinogenesis, rendering them important targets for anticancer drugs. Thymoquinone (TQ) is a natural compound with proven anticancer activities, at least in preclinical studies. TQ can target several kinases, including phosphoinositide 3-kinase (PI3K), mitogen-activated protein kinase (MAPK), Janus kinase/signal transducers and activators of transcription (JAK/STAT), polo-like kinase 1 (PLK1), and tyrosine kinase in different cancer cells and animal models. Inhibiting the activity of kinases or suppressing their expression might be among the mechanisms of TQ anticancer activity. In this review, we discuss the role of TQ in kinase regulation in different cancer models.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2020        PMID： 32721537     DOI： 10.1016/j.drudis.2020.07.019

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  7 in total

1.  Degradation of Signal Transducer and Activator of Transcription Proteins in Cancer Therapeutics.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2020-12-11       Impact factor: 4.345

2.  Thymoquinone, a Dietary Bioactive Compound, Exerts Anti-Inflammatory Effects in Colitis by Stimulating Expression of the Colonic Epithelial PPAR-γ Transcription Factor.

Authors:  Balaji Venkataraman; Saeeda Almarzooqi; Vishnu Raj; Abdullah T Alhassani; Ahmad S Alhassani; Khadijah J Ahmed; Veedamali S Subramanian; Shreesh K Ojha; Samir Attoub; Thomas E Adrian; Sandeep B Subramanya
Journal:  Nutrients       Date:  2021-04-17       Impact factor: 5.717

Review 3.  Targeting microRNAs with thymoquinone: a new approach for cancer therapy.

Authors:  Mina Homayoonfal; Zatollah Asemi; Bahman Yousefi
Journal:  Cell Mol Biol Lett       Date:  2021-10-09       Impact factor: 5.787

Review 4.  Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer.

Authors:  Manzar Alam; Shoaib Alam; Anas Shamsi; Mohd Adnan; Abdelbaset Mohamed Elasbali; Waleed Abu Al-Soud; Mousa Alreshidi; Yousef MohammedRabaa Hawsawi; Anitha Tippana; Visweswara Rao Pasupuleti; Md Imtaiyaz Hassan
Journal:  Front Oncol       Date:  2022-03-25       Impact factor: 6.244

Review 5.  Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis.

Authors:  Ravi Raj Pal; Vasundhara Rajpal; Priya Singh; Shubhini A Saraf
Journal:  Pharmaceutics       Date:  2021-05-22       Impact factor: 6.321

Review 6.  Multiple Myeloma Inhibitory Activity of Plant Natural Products.

Authors:  Karin Jöhrer; Serhat Sezai Ҫiҫek
Journal:  Cancers (Basel)       Date:  2021-05-29       Impact factor: 6.639

7.  Gene Expression Profiling and Protein Analysis Reveal Suppression of the C-Myc Oncogene and Inhibition JAK/STAT and PI3K/AKT/mTOR Signaling by Thymoquinone in Acute Myeloid Leukemia Cells.

Authors:  Belal Almajali; Muhammad Farid Johan; Abdullah Saleh Al-Wajeeh; Wan Rohani Wan Taib; Imilia Ismail; Maysa Alhawamdeh; Nafe M Al-Tawarah; Wisam Nabeel Ibrahim; Futoon Abedrabbu Al-Rawashde; Hamid Ali Nagi Al-Jamal
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.